A Prospective Blood Collection Study to Assess the Immunogenicity of Homologous Booster Combinations of COVID-19 Vaccines Available Under Emergency Use Authorization Among Adults of 18 Years and Older.

The purpose of this study is to assess the immunogenicity of nationally available pre-defined homologous booster vaccination of a SARS-CoV-2 WHO EUA qualified vaccination in adults aged 18 years and older

Start Date01 Feb 2023

Sponsor / Collaborator

SK bioscience Co., Ltd.

[+1]

NCT06429020 / CompletedNot ApplicableIIT

Sonography for COVID-19 Vaccines Related Reactive Lymphadenopathy: A Retrospective Study

This study aimed to provide vast clinical information to facilitate breast sonographic examination for participants who underwent recent SARS-CoV-2 vaccination.
Among different SARS-CoV-2 vaccines in the Asian Taiwanese population, reactive axillary lymphadenopathy was investigated through breast sonographic findings and clinical data analysis. The sample included participants with recent vaccinations by different brands approved in Taiwan.

Start Date01 Jan 2023

Sponsor / Collaborator

Chi Mei Medical Center

NCT05343871 / CompletedPhase 4IIT

Randomized Controlled Trial to Assess the Immunogenicity and Safety of Full Versus Fractional Dose of Pfizer/BioNTech, AstraZeneca, and Sinovac COVID-19 Vaccines Given as a Booster Dose at Least 6 Months After Primary Vaccination Series or PCR-confirmed Infection With SARS-CoV-2 in Healthy Adults

Since the emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen in late 2019, millions of people around the world have fallen ill and died from coronavirus disease 2019 (COVID-19), with variant-fueled case spikes causing repeated cycles of morbidity and mortality. The rapid development and emergency use authorization of vaccines against SARS-CoV-2 presents an enormous opportunity to protect populations, but bottlenecks in production have led to demand for vaccines that far outpaces supply. This project will investigate the immunogenicity of fractional doses of SARS-CoV-2 vaccines given a minimum of six months following an initial two-dose schedule or following natural immunity via documented infection. The consortium of research partners from the Sabin Vaccine Institute, Aga Khan University, Fundação Oswaldo Cruz (Fiocruz), and Stanford University will recruit volunteers to receive a full or fractional booster dose of BNT162b2, AZD1222 or Sinovac following receipt of their primary vaccination series or PCR-confirmed natural infection in Pakistan. The research team will follow participants for six months from boosting, with blood draws at baseline, 28 days, 3 months and 6 months, and measure sero-response rate (SRR) by anti-Spike immunoglobulin G (IgG) binding enzyme-linked immunosorbent assay (ELISA) with the ultimate aim of identifying whether fractional doses provide a similar immune response compared to full doses of vaccine.

Start Date05 Jul 2022

Sponsor / Collaborator

Albert B. Sabin Vaccine Institute, Inc.

[+3]

100 Clinical Results associated with COVID-19 Vaccine (ChAdOx1-S [recombinant])(AstraZeneca Plc)

100 Translational Medicine associated with COVID-19 Vaccine (ChAdOx1-S [recombinant])(AstraZeneca Plc)

100 Patents (Medical) associated with COVID-19 Vaccine (ChAdOx1-S [recombinant])(AstraZeneca Plc)

1,579

Literatures (Medical) associated with COVID-19 Vaccine (ChAdOx1-S [recombinant])(AstraZeneca Plc)

01 Jan 2025·VACCINE

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial

Article

Author: Thiem, Vu Dinh ; Van Be, Le ; Raghunandan, Rama ; Van Thom, Nguyen ; Escarrega, E Alexandar ; Anh, Dang Duc ; Thang, Tran Cong ; Ha, Vu Hai ; Huong, Nguyen Mai ; Raskin, Ariel ; Thai, Duong Huu ; Krammer, Florian ; Flores, Jorge ; Sette, Alessandro ; Carreño, Juan Manuel ; Innis, Bruce L ; Mercer, Laina D ; Mateus, Jose ; Weiskopf, Daniela

Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and lower-middle-income countries is needed. NDV-HXP-S is an inactivated egg-based recombinant Newcastle disease virus vaccine expressing the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A public sector manufacturer in Vietnam assessed the immunogenicity of NDV-HXP-S (COVIVAC) relative to an authorized vaccine. This phase 2 stage of a randomised, observer-blind, controlled, phase 1/2 trial was conducted at three community health centers in Thai Binh Province, Vietnam. Healthy males and non-pregnant females, 18 years of age and older, were eligible. Participants were randomised by age (18-59, ≥60 years) to receive one of three treatments by intramuscular injection twice, 28 days apart: COVIVAC at 3 μg or 6 μg, or AstraZeneca COVID-19 vaccine VAXZEVRIA™. Participants and personnel assessing outcomes were masked to treatment. The vaccine dose was selected based on Phase 1 results. A 6 μg dose was chosen to explore the immunogenicity gain over the 3-μg dose. The study's aim is to evaluate the safety and immunogenicity of COVIVAC at two dose levels compared to VAXZEVRIA, the most commonly used COVID-19 vaccine in Vietnam. The main outcome was the induction of 50% neutralising antibody titers against vaccine-homologous pseudotyped virus 14 days (day 43) and 6 months (day 197) after the second vaccination by age group. The primary immunogenicity and safety analyses included all participants who received one dose of the vaccine. ClinicalTrials.govNCT05940194. During August 10-23, 2021, 737 individuals were screened, and 374 were randomised (124-125 per group); all subjects received vaccine dose one and all but three received doses two four weeks later. Subjects 18-59 years of age achieved the following geometric mean titers of PNA 14 days after vaccine dose two: 153⋅28 (95 % CI 124·2-189⋅15) for COVIVAC 3 μg, 176⋅2 (95 % CI 141⋅45-220.27) for COVIVAC 6 μg, and 99⋅92(95 % CI 80.80-123⋅56) for VAXZEVRIA. Subjects ≥60 years of age also achieved potent geometric mean titers of PNA at the same timepoint: 183⋅57 (95 % CI 133.4-252⋅61) for COVIVAC 3 μg, 257⋅87 (95 % CI 181⋅6-367⋅18) for COVIVAC 6 μg, and 79⋅49(95 % CI 55⋅68-113⋅4) for VAXZEVRIA. On day 43, the geometric mean fold rise of 50 % neutralising antibody titers for subjects age 18-59 years was 31·20 (COVIVAC 3 μg N = 82, 95 % CI 25·14-38·74), 35·80 (COVIVAC 6 μg; N = 83, 95 % CI 29·03-44·15), 18·85 (VAXZEVRIA; N = 82, 95 % CI 15·10-23·54), and for subjects age ≥ 60 years was 37·27 (COVIVAC 3 μg; N = 42, 95 % CI 27·43-50·63), 50·10 (COVIVAC 6 μg; N = 40, 95 % CI 35·46-70·76), 16·11 (VAXZEVRIA; N = 40, 95 % CI 11·73-22·13). Among subjects seronegative for anti-S IgG at baseline, the day 43 geometric mean titer ratio of neutralising antibody (COVIVC 6 μg/VAXZEVRIA) was 1·77 (95 % CI 1·30-2·40) for subjects age 18-59 years and 3·24 (95 % CI 1·98-5·32) for subjects age ≥ 60 years. On day 197, the age-specific ratios were 1·11 (95 % CI 0·51-2·43) and 2·32 (0·69-7·85). Vaccines were well tolerated; reactogenicity was predominantly mild and transient. The percentage of subjects with unsolicited adverse events (AEs) during 28 days after vaccinations was similar among treatments (COVIVAC 3 μg 29·0 %, COVIVAC 6 μg 23·2 %, VAXZEVRIA 31·2 %); no vaccine-related AE was reported. Considering that induction of neutralising antibodies against SARS-CoV-2 has been correlated with the efficacy of COVID-19 vaccines, including VAXZEVRIA, our results suggest that vaccination with COVIVAC may afford clinical benefit matching or exceeding that of the VAXZEVRIA vaccine. ClinicalTrials.govNCT05940194.

31 Dec 2024·Human vaccines & immunotherapeutics

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines

Article

Author: Hu, Branda ; de Los Reyes, Mari Rose A. ; Ambrosino, Donna ; Gao, Faith ; Roa, Camilo C. ; Siber, George ; Ilagan, Hannalyn ; Han, Htay Htay ; Plennevaux, Eric ; Smolenov, Igor ; Clemens, Ralf

We assessed the non-inferiority of homologous boosting compared with heterologous boosting with the recombinant protein vaccine, SCB-2019, in adults previously immunized with different COVID-19 vaccines. Three equal cohorts (N ~ 420) of Philippino adults (18-80 years) previously immunized with Comirnaty, CoronaVac or Vaxzevria COVID-19 vaccines were randomized 1:1 to receive homologous or heterologous (SCB-2019) boosters. Neutralizing antibodies against prototype SARS-CoV-2 (Wuhan-Hu-1) were measured in all participants and against Delta variant and Omicron sub-lineages in subsets (30‒50 per arm) 15 days after boosting. Participants recorded solicited adverse events for 7 days and unsolicited and serious adverse events until Day 60. Prototype SARS-CoV-2 neutralizing responses on Day 15 after SCB-2019 were statistically non-inferior to homologous Vaxzevria boosters, superior to CoronaVac, but lower than homologous Comirnaty. Neutralizing responses against Delta and Omicron BA.1, BA.2, BA.4 and BA.5 variants after heterologous SCB-2019 were higher than homologous CoronaVac or Vaxzevria, but lower than homologous Comirnaty. Responses against Omicron BF.7, BQ.1.1.3, and XBB1.5 following heterologous SCB-2019 were lower than after homologous Comirnaty booster but significantly higher than after Vaxzevria booster. SCB-2019 reactogenicity was similar to CoronaVac or Vaxzevria, but lower than Comirnaty; most frequent events were mild/moderate injection site pain, headache and fatigue. No vaccine-related serious adverse events were reported. Heterologous SCB-2019 boosting was well tolerated and elicited neutralizing responses against all tested SARS-COV-2 viruses including Omicron BA.1, BA.2, BA.4, BA.5, BF.7, BQ.1.1.3, and XBB1.5 sub-lineages that were non-inferior to homologous boosting with CoronaVac or Vaxzevria, but not homologous Comirnaty booster.

31 Dec 2024·Virulence

Humoral responses to multiple SARS-CoV-2 variants after two doses of vaccine in kidney transplant patients

Article

Author: Syu, Guan-Da ; Shih, Hsi-Chang ; Ho, Tzong-Shiann ; Chang, Shen-Shin ; Du, Pin-Xian ; Tsai, Pei-Shan

Background: The COVID-19 pandemic has led to millions of fatalities globally. Kidney transplant (KT) patients, given their comorbidities and under immunosuppressant drugs, are identified as a high-risk group. Though vaccination remains pivotal for pandemic control, some studies indicate that KT exhibits diminished immune reactions to SARS-CoV-2 vaccines. Therefore, evaluating the vaccine responses in KT, especially the humoral responses against emergent variants is crucial.Methods: We developed a multiplexed SARS-CoV-2 variant protein microarray, incorporating the extracellular domain (ECD) and the receptor binding domain (RBD) of the spike proteins from the variants. This was employed to investigate the collective humoral responses after administering two doses of mRNA-1273 and AZD1222 vaccines in KT under immunosuppressive drugs and in healthy controls.Results: After two doses of either mRNA-1273 or AZD1222, the KT generally showed lower surrogate neutralizing and total antibodies against spike ECD in multiple variants compared to healthy controls. Although two doses of mRNA-1273 induced 1.5-2 fold more surrogate neutralizing and total antibodies than AZD1222 in healthy controls, the KT subjects with two doses of mRNA-1273 generally exhibited higher surrogate neutralizing but similar total antibodies against spike ECD in multiple variants. There were moderate to high correlations between the surrogate neutralizing and total antibodies against spike ECDs.Conclusion: This study offers pivotal insights into the relative vulnerability of KT concerning humoral immunity and the evolving mutations of SARS-CoV-2. Such findings are useful for evaluating vaccine responses and recommending vaccine episodes for KT.

118

News (Medical) associated with COVID-19 Vaccine (ChAdOx1-S [recombinant])(AstraZeneca Plc)

06 Nov 2024

·www.globenewswire.com

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

OXFORD, United Kingdom, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease, provided an overview of business updates and announced financial results for the third quarter of 2024. “We continue our strong execution on our clinical trials, completing enrollment in the HBV003 trial of VTP-300 in chronic hepatitis B, and advancing VTP-1000 in celiac disease into the clinic with the first in human study of the novel SNAP-TI platform,” said Dr. Leon Hooftman, Chief Medical Officer of Barinthus Bio. “We expect a data rich fourth quarter from the VTP-300 chronic hepatitis B program, with updated interim readouts from both the HBV003 and IM-PROVE II trials accepted as late-breaking abstracts at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2024. These updates will provide more mature data than previously disclosed as participants progress and move towards a potential functional cure.” Third Quarter 2024 and Recent Corporate Developments VTP-300 (Chronic hepatitis B) In September 2024, enrollment was completed in the HBV003 trial of VTP-300 in 121 adult participants with chronic hepatitis B. The Phase 2b trial is designed to obtain critical dosing information for a potential functional cure regimen for chronic hepatitis B, with participants receiving VTP-300 and low-dose (LD) nivolumab. Earlier this year, interim data from the HBV003 trial was presented at the European Association for the Study of the Liver (EASL) Congress and demonstrated that treatment with VTP-300 and LD nivolumab was generally well-tolerated and led to a sustained decline in Hepatitis B surface antigen (HBsAg) levels. Seventy-six percent of participants (n=16/21) assessed for nucleos(t)ide analogue (NUC) therapy discontinuation met the criteria. Sixty-seven percent of participants (n=14/21) assessed for NUC discontinuation had HBsAg <10 IU/mL at Week 24 or later. Nineteen percent of the eligible participants (n=4/21) reached undetectable levels of HBsAg, with 2 of these patients maintaining undetectable levels for over 16 weeks. VTP-1000 (Celiac Disease) In September 2024, we initiated the first-in-human Phase 1 AVALON trial of VTP-1000 in adults with celiac disease. The randomized, placebo-controlled clinical trial, which includes a controlled gluten challenge, will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-1000. VTP-850 (Prostate Cancer) In October 2024, we announced that the PCA001 trial of VTP-850 in men with rising prostate-specific antigen (PSA) after definitive local therapy for prostate cancer (i.e., biochemical recurrence) had completed patient enrollment of 22 participants. The Phase 1 trial is designed to evaluate safety and efficacy, as measured by PSA and T cell response. We expect to have data from the Phase 1 trial in the first half of 2025. Financial Update In October 2024, we were informed that an additional $15.0 million of revenue was due to the Company from Oxford University Innovation (OUI) in relation to the Company's share of royalties received by OUI, as a result of prior commercial sales of Vaxzevria® by AstraZeneca. We expect that this additional cash, when received, will enable us to fund our research and development plans further into the second quarter of 2026. Upcoming Milestones VTP-300 (Chronic hepatitis B) In the fourth quarter of 2024, we expect to announce updated data from the VTP-300 program in ongoing clinical trials in chronic hepatitis B at AASLD – The Liver Meeting® 2024 scheduled from November 15-19, 2024 in San Diego, CA: Updated interim data from HBV003, the Phase 2b trial evaluating additional dosing of VTP-300 and timing of PD-1 inhibition, accepted as a late-breaking oral presentation.Updated interim data from the Phase 2a IM-PROVE II clinical trial evaluating the combination of VTP-300 and Arbutus Biopharma’s imdusiran, accepted as a late-breaking poster. VTP-1000 (Celiac Disease) In the first half of 2025, we expect to announce data from the single ascending dose part of the Phase 1 AVALON trial of VTP-1000 in adults with celiac disease. VTP-850 (Prostate Cancer) In the first half of 2025, we expect to announce results of the Phase 1 PCA001 trial of VTP-850 in men with rising PSA after definitive local therapy for prostate cancer (i.e., biochemical recurrence). Third Quarter 2024 Financial Highlights Cash position: As of September 30, 2024, cash, cash equivalents and restricted cash were $106.1 million, compared to $117.8 million as of June 30, 2024. The net cash used in operating activities was $18.2 million in the third quarter of 2024, primarily resulting from the development of our pipeline and ongoing clinical trials, offset by $6.2 million due to the effect of foreign exchange rates on cash balances. Based on our current operating plans, we expect our available resources to fund operating expenses and capital expenditure requirements into the second quarter of 2026.Revenue: Revenue consisted of $15.0 million in the third quarter of 2024 compared to nil in the second quarter of 2024. Revenue was comprised of the Company’s share of royalties received by OUI as a result of prior commercial sales of Vaxzevria® by AstraZeneca.There is no expectation of additional payments or that we will be notified of such payments in a timely manner.Research and development expenses: Research and development expenses were $11.1 million in the third quarter of 2024 compared to $11.7 million in the second quarter of 2024, with the decrease mainly attributable to a reduction in personnel-related costs as a result of the pipeline prioritization earlier in the year. The quarter-on-quarter R&D expense per program is outlined in the following table. Period ended Three monthsendedSeptember 30,2024 Three monthsended June30, 2024 Change $000 $000 $000 Direct research and development expenses by program: VTP-200 HPV $246 $383 $(137)VTP-300 HBV 2,748 3,034 (286)VTP-500 MERS1 40 304 (264)VTP-600 NSCLC/ESCC2 108 24 84 VTP-850 Prostate cancer 914 414 500 VTP-1000 Celiac 1,751 1,371 380 Other and earlier stage programs 707 908 (201)Total direct research and development expenses $6,514 $6,438 $76 Indirect research and development expenses: Personnel-related (including share-based compensation)3 3,871 4,763 (892)Facility related 214 342 (128)Other indirect costs 540 119 421 Total indirect research and development expenses 4,625 5,224 (599)Total research and development expense $11,139 $11,662 $(523) 1 The development of VTP-500 is funded pursuant to an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI). 2 The VTP-600 NSCLC/Esophageal Squamous-Cell Carcinoma (ESCC) Phase 1/2a trial is sponsored by Cancer Research UK. 3 This includes $0.6 million of personnel-related indirect expenses relating to time spent progressing the VTP-500 MERS program funded by CEPI. General and administrative expenses: General and administrative expenses were $13.4 million in the third quarter of 2024, compared to $7.2 million in the second quarter of 2024. The increase of $6.2 million relates primarily to a loss of $7.7 million on foreign exchange in the third quarter of 2024, compared to a loss of $0.1 million in the second quarter of 2024.Net loss: For the third quarter of 2024, we generated a net loss attributable to shareholders of $8.1 million, or $(0.21) per share on both basic and fully diluted bases, compared to a net loss attributable to shareholders of $16.9 million, or $(0.43) per share on both basic and fully diluted bases in the second quarter of 2024. About Barinthus Bio Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a focused pipeline built around our proprietary platform technologies, Barinthus Bio is advancing immunotherapeutic product candidates in infectious diseases and autoimmunity, including: VTP-300, that utilizing our ChAdOx/MVA platform designed as a potential component of a functional cure for chronic HBV infection and VTP-1000, utilizing our SNAP-Tolerance Immunotherapy (SNAP-TI) platform and is designed to treat people with celiac disease. Barinthus Bio is also conducting a Phase 1 clinical trial for VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer. Barinthus Bio’s differentiated technology platforms and therapeutic approach, coupled with deep scientific expertise and focus on clinical development, uniquely positions the company to navigate towards delivering treatments that improve the lives of people with chronic infectious diseases and autoimmunity. For more information, visit www.barinthusbio.com. Barinthus Bio intends to use the Investors section of its website, its X (formerly known as Twitter) account at @Barinthusbio and its LinkedIn account at linkedin.com/company/barinthus-bio as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Barinthus Bio’s website, its X account and its LinkedIn account in addition to following Barinthus Bio’s press releases, SEC filings, public conference calls, presentations, and webcasts. Forward Looking Statements This press release contains forward-looking statements regarding Barinthus Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words “may,” “will,” “plan,” “forward,” “encouraging,” “believe,” “potential,” “expect,” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include, without limitation, express or implied statements regarding our future expectations, plans and prospects, including our product development activities and clinical trials, including timing for readouts of any preliminary, interim or final data for any of our programs, our anticipated regulatory filings and approvals, our cash runway, the potential benefits of our product candidates, and our ability to develop and advance our current and future product candidates and programs. Any forward-looking statements in this press release are based on our management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the success, cost and timing of our pipeline development activities and planned and ongoing clinical trials, including the risk that the timing for preliminary, interim or final data or initiation of our clinical trials may be delayed, the risk that interim or topline data may not reflect final data or results, our ability to execute on our strategy, regulatory developments, the risk that we may not achieve the anticipated benefits of our pipeline prioritization and corporate restructuring, our ability to fund our operations and access capital, our cash runway, including the risk that our estimate of our cash runway may be incorrect, global economic uncertainty, including disruptions in the banking industry, the conflicts in Ukraine, Israel and Gaza, and other risks identified in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We expressly disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. BARINTHUS BIOTHERAPEUTICS PLC CONSOLIDATED BALANCE SHEETS (IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS) (UNAUDITED) September 30,2024 December 31,2023ASSETS Cash, cash equivalents and restricted cash$106,102 $142,090 Contract asset - related parties 14,969 — Research and development incentives receivable 5,403 4,908 Prepaid expenses and other current assets 8,180 9,907 Total current assets 134,654 156,905 Goodwill 12,209 12,209 Property and equipment, net 10,719 11,821 Intangible assets, net 22,737 25,108 Right of use assets, net 7,444 7,581 Other assets 926 882 Total assets$188,689 $214,506 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable 3,076 1,601 Accrued expenses and other current liabilities 7,966 9,212 Deferred income 2,044 — Operating lease liability - current 1,986 1,785 Total current liabilities 15,072 12,598 Non-current liabilities: Operating lease liability - non-current 10,683 11,191 Contingent consideration 1,610 1,823 Other non-current liabilities 1,406 1,325 Deferred tax liability, net 457 574 Total liabilities$29,228 $27,511 Commitments and contingencies (Note 15) Stockholders’ equity: Ordinary shares, £0.000025 nominal value; 39,542,518 shares authorized, issued and outstanding (December 31, 2023: authorized, issued and outstanding: 38,643,540) 1 1 Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2023: authorized, issued and outstanding: 63,443) 86 86 Additional paid-in capital 391,882 386,602 Accumulated deficit (217,124) (176,590)Accumulated other comprehensive loss – foreign currency translation adjustments (15,551) (23,315)Total stockholders’ equity attributable to Barinthus Biotherapeutics plc shareholders 159,294 186,784 Noncontrolling interest 167 211 Total stockholders’ equity$159,461 $186,995 Total liabilities and stockholders’ equity$188,689 $214,506 BARINTHUS BIOTHERAPEUTICS PLC CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS) (UNAUDITED) Three months ended Nine months ended September 30,2024 September 30,2023 September 30,2024 September 30,2023License revenue 1$14,969 $— $14,969 $802 Total revenue 14,969 — 14,969 802 Operating expenses Research and development 11,139 15,144 33,926 38,501 General and administrative 13,420 961 26,615 26,227 Total operating expenses 24,559 16,105 60,541 64,728 Other operating income 210 — 992 — Loss from operations (9,380) (16,105) (44,580) (63,926)Other income/(expense): Interest income 631 196 2,041 2,306 Interest expense (17) (7) (41) (21)Research and development incentives 608 1,205 1,895 2,921 Other income/(expense) 26 (2) 46 308 Total other income, net 1,248 1,392 3,941 5,514 Loss before income tax (8,132) (14,713) (40,639) (58,412)Tax benefit 3 603 47 2,255 Net loss (8,129) (14,110) (40,592) (56,157)Net loss attributable to noncontrolling interest 15 38 58 103 Net loss attributable to Barinthus Biotherapeutics plc shareholders (8,114) (14,072) (40,534) (56,054) Weighted-average ordinary shares outstanding, basic 39,419,447 38,533,833 39,079,259 38,320,208 Weighted-average ordinary shares outstanding, diluted 39,419,447 38,533,833 39,079,259 38,320,208 Net loss per share attributable to ordinary shareholders, basic$(0.21) $(0.37) $(1.04) $(1.46)Net loss per share attributable to ordinary shareholders, diluted$(0.21) $(0.37) $(1.04) $(1.46) Net loss$(8,129) $(14,110) $(40,592) $(56,157)Other comprehensive gain/(loss) – foreign currency translation adjustments 9,191 (7,820) 7,778 2,364 Comprehensive income/(loss) 1,062 (21,930) (32,814) (53,793)Comprehensive loss attributable to noncontrolling interest 5 48 44 100 Comprehensive income/(loss) attributable to Barinthus Biotherapeutics plc shareholders$1,067 $(21,882) $(32,770) $(53,693) 1 Includes license revenue from related parties for the three and nine months ended September 30, 2024 of $15.0 million (three and nine months ended September 30, 2023: nil and $0.8 million, respectively). IR contacts:Christopher M. Calabrese Managing Director LifeSci Advisors+1 917-680-5608ccalabrese@lifesciadvisors.com Kevin GardnerManaging DirectorLifeSci Advisors+1 617-283-2856kgardner@lifesciadvisors.com Media contact:Audra FriisSam Brown, Inc.+1 917-519-9577audrafriis@sambrown.com Company contact:Jonothan BlackbournIR & PR ManagerBarinthus Bioir@barinthusbio.com

Phase 2Clinical ResultPhase 1Financial Statement

17 May 2024

·www.fiercebiotech.com

Very rare COVID vaccine-related blood clots share genes with condition linked to common cold

With regards to the AstraZeneca and Johnson & Johnson vaccines, the findings concretely implicate the adenovirus as the culprit behind rare cases of vaccine-induced immune thrombocytopenia and thrombosis. The rare, deadly blood clots triggered by an autoimmune response to the COVID-19 vaccines from Johnson & Johnson and AstraZeneca seem to be caused by a gene that’s also responsible for an unusual but almost identical reaction to the virus that causes the common cold. The findings could have implications for future vaccines. In a letter published May 15 in The New England Journal of Medicine, an international team of scientists explained that people who carry certain variants of a gene called IGLV3-21*02 are predisposed to developing both vaccine-induced immune thrombocytopenia and thrombosis (VITT) and the same type of reaction after infection with the adenovirus. Both the J&J and AstraZeneca vaccines are delivered to the body in adenovirus vectors, which explains why the etiology of the conditions is the same. “Our findings have the important clinical implication that lessons learned from VITT are applicable to rare cases of blood clotting after adenovirus infections, as well as having implications for vaccine development," Tom Gordon, M.D., Ph.D., of Flinders University, who led the co-study, said in a press release. Theodore Warkentin, M.D. from McMaster University in Canada and Andreas Greinacher, M.D., from Greifswald University in Germany also led the work. AstraZeneca’s vaccine, Vaxzevria, was dogged by reports of VITT not long after the shot rolled out in Europe. Soon after, news of VITT in six U.S. patients who took the J&J vaccine emerged as well, prompting officials to pause it to investigate and later restrict its use. It was removed from the market entirely two years later. AstraZeneca’s shot remained available in some parts of Europe until May 2024, when the company requested its marketing approval be revoked due to a decline in demand. As of May 2023, the same month J&J’s vaccine was pulled, there had been 60 cases of VITT reported in the U.S., including nine deaths. The last count for VITT cases related to AstraZeneca’s vaccine in the U.K. before it was taken off the market was 455, with 81 deaths, according to the U.K.'s healthcare watchdog the Medicines and Healthcare products Regulatory Agency. The reactions are caused by antibodies against the protein platelet factor 4, or PF4, a protein involved in blood clotting. In 2022, Gordon and his colleagues used a screening method called antibody proteomics to show that antibodies expressed by a variant of IGLV3-21*02 targeted PF4. Genetic analysis of five patients who developed VITT after getting the AstraZeneca vaccine showed that all of them had this gene variant. Then, in 2023, another research team reported that adenovirus infection led to the same anti-PF4 antibodies and immune thrombocytopenia and thrombosis. The pathogenesis was identical to VITT; this was the first signal of an “anti-PF4 disorder,” as the researchers called it, that might share its etiology. The two groups teamed up to validate their hypotheses. When they analyzed the structure of the anti-PF4 antibodies from patients in each group and superimposed them, they found they were “extremely similar,” as they wrote in the NEJM letter. “Such an extraordinary level of autoantibody fingerprint identity between two disorders—at the level of patient-derived antibodies—strongly indicates that VITT and the anti-PF4 disorder that is associated with adenoviral infection are a distinct class of adverse immune responses associated with viral (presumably, adenoviral) structures,” the researchers wrote. With regards to the AstraZeneca and J&J vaccines, the findings concretely implicate the adenovirus as the cause of VITT rather than other ingredients. But while the researchers know that the immune response to the virus triggers the creation of antibodies to PF4, they still need to identify the antigen, or the proteins or sugars on the virus, that stimulates their creation. This would potentially enable them to genetically engineer the adenovirus vector so it doesn’t have the antigen and, thus, makes adenovirus-based vaccines safer. The team behind the new NEJM paper is currently investigating the antigenic epitope, or the part of the antigen the immune system recognizes, Gordon confirmed to Fierce Biotech Research in an email. Previously, the Flinders scientists said it may be possible to create a genetic test that can identify patients at risk of VITT as well as to come up with a therapy that neutralizes the anti-PF4 antibodies. In a statement to Bloomberg earlier this week, an AstraZeneca spokesperson said the company “welcomes any further examination of the possible underlying mechanism of thrombosis with thrombocytopenia syndrome.” J&J told the outlet in an email that it supports the research as well and that “more data are needed to fully understand potential factors that may be associated with this rare event.”

VaccineDrug ApprovalClinical Study

13 May 2024

·www.globenewswire.com

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

OXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, announced its financial results for the first quarter of 2024 and provided an overview of the Company’s progress. “So far in 2024 we have continued to make strides across our programs. Notably, we received clearance from the FDA on an IND to progress VTP-1000 in a first in human clinical trial in celiac disease, as well as clearance from the Australian Ethics Committee on this trial. We expect to begin our Phase 1 trial of VTP-1000 in participants with celiac disease in the coming months. Additionally, we reported topline final data from the Phase 1b/2 trial of VTP-200 in participants with persistent high-risk (hr) human papillomavirus (HPV) infections,” said Bill Enright, Chief Executive Officer of Barinthus Bio. "Looking ahead to Q2, we will present additional interim data from our VTP-300 hepatitis B trials at the European Association for the Study of the Liver (EASL) Congress in June. This follows the encouraging data presented at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® in November last year. We will also welcome Dr. Leon Hooftman as our new Chief Medical Officer in June and look forward to him supporting the growth of our robust pipeline and programs.” Recent Corporate Developments Clinical developments VTP-1000 (Celiac Disease): In April 2024, we received clearance from the U.S. FDA on an Investigational New Drug (IND) application, as well as from the Australian regulatory authorities, to progress VTP-1000 in a first in human clinical trial in celiac disease. GLU001 is a randomized, placebo-controlled Phase 1 trial with a controlled gluten challenge to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-1000 in adults with celiac disease. The study is designed in two parts; a single ascending dose part followed by a multiple ascending dose part, each randomized and placebo-controlled with three dose levels. The primary endpoint is assessment of the safety and tolerability of single and multiple dosing, and determination of a dose and schedule for further investigation. The trial also aims to demonstrate proof-of-principle of induction of immune tolerance and early proof-of-concept for VTP-1000, as a potential treatment for celiac disease, based on assessment of pharmacodynamics and preliminary efficacy determined by means of a controlled gluten challenge.VTP-200 (HPV): In April 2024, we announced topline final data from the APOLLO trial, (also known as HPV001) a Phase 1b/2 dose-ranging study of VTP-200 in women with low-grade cervical lesions associated with persistent hrHPV infection. The APOLLO study met its primary safety endpoint, demonstrating that VTP-200 was generally well-tolerated and was administered with no treatment-related grade 3 or higher unsolicited adverse events (AEs) and no treatment-related serious AEs. Positive trends in clearance rate for both hrHPV (60%, Group 2) and cervical lesions (67%, Groups 2 and 5), were observed in the groups receiving the highest ChAdOx dose. Pooled data from the five different active dose groups demonstrated no statistically significant improvement in either hrHPV or cervical lesion clearance in comparison to the placebo group.VTP-300 (HBV): In April 2024, abstracts on interim data from HBV003 and AB-729-202 were accepted for presentation at the upcoming EASL Congress in Milan, Italy, June 5-8, 2024. Management Team On May 1, 2024, we announced the appointment of Dr. Leon Hooftman as Chief Medical Officer. Dr. Hooftman will join the company on June 3, 2024, and brings significant drug development expertise across a broad array of therapeutic areas including immunology, autoimmunity, hematology, oncology and infectious diseases. Upcoming Milestones In the second quarter of 2024, the Company expects to: VTP-300 (HBV): Present interim data from HBV003, our Phase 2b trial evaluating additional dosing of VTP-300 and timing of PD-1 inhibition, in participants with chronic hepatitis B (CHB) on nucleos(t)ide analogue (NUC) therapy at the EASL Congress in June.VTP-300 (HBV): Announce interim data from the Phase 2a AB-729-202 clinical trial evaluating the combination of VTP-300 and Arbutus’ imdusiran, in participants with CHB on NUC therapy following presentation at the EASL Congress in June. In the third quarter of 2024, the Company expects to: VTP-1000 (Celiac Disease): Dose the first patient in GLU001, a randomized, placebo-controlled Phase 1 trial with a controlled gluten challenge to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-1000 in adults with celiac disease. This timing update is based on the latest feasibility and expected site set-up timelines. First Quarter 2024 Financial Highlights Cash position: As of March 31, 2024, cash, cash equivalents and restricted cash was $130.0 million, compared to $142.1 million as of December 31, 2023. The cash used in operating activities was $11.8 million in the first quarter of 2024, primarily resulting from development of our pipeline and ongoing clinical trials. Based on current research and development plans, the Company expects its cash runway to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2025.Revenue: Revenue was nil in the first quarter of 2024 compared to $0.5 million in the first quarter of 2023 and was due to no commercial sales of Vaxzevria® by AstraZeneca in 2024.Research and development expenses: Research and development expenses were $11.1 million in the first quarter of 2024 compared to $9.8 million in the first quarter of 2023, with the increase mainly attributable to hiring of personnel and increased costs related to the advancement of our programs. The quarter-on-quarter R&D expense per program is outlined in the following table. Year ended Three monthsended March31, 2024 Three monthsended March31, 2023 Change $000 $000 $000 Direct research and development expenses by program: VTP-200 HPV $1,253 $1,338 $(85)VTP-300 HBV 1,913 2,118 (205)VTP-500 MERS1 172 — 172 VTP-600 NSCLC2 164 275 (111)VTP-850 Prostate cancer 178 215 (37)VTP-1000 Celiac 1,374 1,572 (198)Other and earlier stage programs3 784 280 504 Total direct research and development expenses $5,838 $5,798 $40 Indirect research and development expenses: Personnel-related (including share-based compensation) 4,335 3,601 734 Facility related 390 371 19 Other indirect costs 562 44 518 Total indirect research and development expenses 5,287 4,016 1,271 Total research and development expense $11,125 $9,814 $1,311 1 The development of VTP-500 is funded pursuant to an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI). 2 The VTP-600 NSCLC Phase 1/2a trial is sponsored by Cancer Research UK. 3 Research and development expenses related to VTP-1100 HPV Cancer were previously included with VTP-1000 Celiac but are now included in 'Other and earlier stage programs' because we are focusing resources on other clinical programs and deferring the IND application for VTP-1100 in HPV cancer. General and administrative expenses: General and administrative expenses were $6.0 million in the first quarter of 2024, compared to $12.1 million in the first quarter of 2023. The decrease of $6.1 million relates primarily to a gain of $1.2 million on foreign exchange for the first quarter of 2024, compared to a loss of $3.5 million for the first quarter of 2023, a decrease in personnel expenses, including share-based payment charges of $0.8 million, primarily due to a reduction in non-cash share-based payment charges, and a decrease in insurance costs of $0.9 million due to a reduction in insurance premiums.Net loss: For the first quarter of 2024, the Company generated a net loss attributable to its shareholders of $15.5 million, or $(0.40) per share on both basic and fully diluted bases, compared to a net loss attributable to its shareholders of $18.2 million, or $(0.48) per share on both basic and fully diluted bases in the first quarter of 2023. About Barinthus Bio Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a broad pipeline, built around three proprietary platform technologies: ChAdOx, MVA and SNAP, Barinthus Bio is advancing a pipeline of five product candidates across a diverse range of therapeutic areas, including: VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-Tolerance Immunotherapy (TI) platform to treat patients with celiac disease; and VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer. Barinthus Bio’s proven scientific expertise, diverse portfolio and focus on pipeline development uniquely positions the company to navigate towards delivering treatments for people with infectious diseases, autoimmunity and cancers that have a significant impact on their everyday lives. For more information, visit www.barinthusbio.com. Forward Looking Statements This press release contains forward-looking statements regarding Barinthus Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words “may,” “will,” “plan,” “forward,” “encouraging,” “believe,” “potential,” "expect", and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include, without limitation, express or implied statements regarding our future expectations, plans and prospects, including our product development activities and clinical trials, including timing for readouts of any preliminary, interim or final data for any of our programs, the timing for initiation of any clinical trials, including dosing of the first patient in GLU001 for VTP-1000, our anticipated regulatory filings and approvals, our preliminary estimated cash and cash equivalents, our cash runway, and our ability to develop and advance our current and future product candidates and programs. Any forward-looking statements in this press release are based on our management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the success, cost and timing of our pipeline development activities and planned and ongoing clinical trials, including the risk that the timing for preliminary, interim or final data or initiation of our clinical trails may be delayed, our ability to execute on our strategy, regulatory developments, our ability to fund our operations and access capital, our cash runway, including the risk that our estimate of our cash runway may be incorrect, global economic uncertainty, including disruptions in the banking industry, the conflict in Ukraine, the conflict in Israel and Gaza, and other risks identified in our filings with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We expressly disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.   BARINTHUS BIOTHERAPEUTICS PLC CONSOLIDATED BALANCE SHEETS (IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS) (UNAUDITED) March 31,2024 December 31,2023ASSETS Cash, cash equivalents and restricted cash$129,971 $142,090 Research and development incentives receivable 5,196 4,908 Prepaid expenses and other current assets 7,964 9,907 Total current assets 143,131 156,905 Goodwill 12,209 12,209 Property and equipment, net 11,532 11,821 Intangible assets, net 24,317 25,108 Right of use assets, net 7,408 7,581 Other assets 885 882 Total assets$199,482 $214,506 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable 1,162 1,601 Accrued expenses and other current liabilities 8,330 9,212 Deferred income 1,434 — Operating lease liability - current 1,909 1,785 Total current liabilities 12,835 12,598 Non-Current liabilities: Operating lease liability - non-current 10,897 11,191 Contingent consideration 1,867 1,823 Other non-current liabilities 1,330 1,325 Deferred tax liability, net 537 574 Total liabilities$27,466 $27,511 Commitments and contingencies (Note 15) Stockholders’ equity: Ordinary shares, £0.000025 nominal value; 38,952,956 shares authorized, issued and outstanding (December 31, 2023: authorized, issued and outstanding:38,643,540) 1 1 Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2023: authorized, issued and outstanding:63,443) 86 86 Additional paid-in capital 388,720 386,602 Accumulated deficit (192,079) (176,590)Accumulated other comprehensive loss – foreign currency translation adjustments (24,895) (23,315)Total stockholders’ equity attributable to Barinthus Biotherapeutics plc shareholders 171,833 186,784 Noncontrolling interest 183 211 Total stockholders’ equity$172,016 $186,995 Total liabilities and stockholders’ equity$199,482 $214,506 BARINTHUS BIOTHERAPEUTICS PLC CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS) (UNAUDITED) Three months ended March 31, 2024 March 31, 2023License revenue 1 $— $468 Total revenue — 468 Operating expenses Research and development 11,125 9,814 General and administrative 5,994 12,138 Total operating expenses 17,119 21,952 Other operating income 205 — Loss from operations (16,914) (21,484)Other income/(expense): Interest income 775 1,588 Interest expense (12) — Research and development incentives 594 1,157 Total other income, net 1,357 2,745 Loss before income tax (15,557) (18,739)Tax benefit 37 516 Net loss (15,520) (18,223)Net loss attributable to noncontrolling interest 31 43 Net loss attributable to Barinthus Biotherapeutics plc shareholders (15,489) (18,180) Weighted-average ordinary shares outstanding, basic 38,773,482 38,013,399 Weighted-average ordinary shares outstanding, diluted 38,773,482 38,013,399 Net loss per share attributable to ordinary shareholders, basic $(0.40) $(0.48)Net loss per share attributable to ordinary shareholders, diluted $(0.40) $(0.48) Net loss $(15,520) $(18,223)Other comprehensive (loss)/gain – foreign currency translation adjustments (1,577) 4,580 Comprehensive loss (17,097) (13,643)Comprehensive loss attributable to noncontrolling interest 28 37 Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders $(17,069) $(13,606) 1 Includes license revenue from related parties for the three months ended March 31, 2024 of nil (March 31, 2023: $0.5 million). IR contacts:Christopher M. Calabrese Managing Director LifeSci Advisors+1 917-680-5608ccalabrese@lifesciadvisors.com Kevin GardnerManaging DirectorLifeSci Advisors+1 617-283-2856kgardner@lifesciadvisors.com Media contact:Audra FriisSam Brown, Inc.+1 917-519-9577audrafriis@sambrown.com Company contact:Jonothan BlackbournIR & PR ManagerBarinthus Bioir@barinthusbio.com

Phase 2Phase 1Clinical ResultExecutive ChangeFinancial Statement

100 Deals associated with COVID-19 Vaccine (ChAdOx1-S [recombinant])(AstraZeneca Plc)

External Link

KEGG	Wiki	ATC	Drug Bank
-	COVID-19 Vaccine (ChAdOx1-S [recombinant])(AstraZeneca Plc)	J07B	DB15656

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
COVID-19	GB	AstraZeneca PLC	30 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04568031 (CTgov)	Phase 1/2	COVID-19	256	AZD1222 (Cohort C: AZD1222)	ppqlqbvrfd(opxocrjmqy) = ayhiibavys oetontpclp (jzlkookwgh, zxjfuocnsd - qyfbcyemdc) View more	-	01 Mar 2024
				placebo+AZD1222 (Cohort C: Placebo)	ppqlqbvrfd(opxocrjmqy) = elvciswpcz oetontpclp (jzlkookwgh, ugsruzjrar - pwkehtdnyn) View more
ISN WCN2023	Not Applicable	Renal transplant rejection IL-10 \| TGF-β \| IFN-γ ... View more	171	COVAXIN™	svhzwruxyv(uhwpvqnort) = gwhcggxrtx fuftjxrihd (pecnyowqyj, 398.70 - 2652.45)	Positive	01 Mar 2023
Open Label Extension Study (ACR2022)	Not Applicable	anti-RBD antibody titers	36	Rituximab treated patients with 3rd vaccination with vector vaccine	adulpvihff(cclndusoeg) = one serious adverse event not related to vaccination occurred dcdjawaerh (newclvrrag )	Negative	13 Nov 2022
				Rituximab treated patients with 3rd vaccination with mRNA vaccine
ASN2022	Not Applicable	Hemodialysis complication Maintenance	130	Inactivated Vaccine (Sinovac (SV-SV))	atsmhqsnog(hndnmedlti) = eyhuuhayjh oaxsmoavia (wdjxxpyzid )	Positive	03 Nov 2022
				AZD1222 (AZ-AZ)	atsmhqsnog(hndnmedlti) = gmowmhygky oaxsmoavia (wdjxxpyzid )
NCT04516746 (Pubmed) Manual	Phase 3	COVID-19	32,450	COVID-19 Vaccine	vqhrgquwuu(thlqbgnisw) = uwyoybzctf ixswstpqgm (bifynnrphb ) View more	Positive	15 Sep 2022
				Placebo	vqhrgquwuu(thlqbgnisw) = iwscbirpbi ixswstpqgm (bifynnrphb ) View more
ISTH2022	Not Applicable	COVID-19 anti-platelet factor4/polyanionic antibodies	720	ChAdOx1 nCoV-19	cshjjqzlci(hwodfeeyfq) = rlteiuuokk shlkpvjppd (pvezzfvwlv )	-	09 Jul 2022
ISTH2022	Not Applicable	Thrombotic Thrombocytopenic Purpura, Acquired platelet factor 4	-	ChAdOx1 nCoV-19	vtpavrhaqn(cfbinqzxzq) = nimtlmlifa kronnnolib (lrkbshejup ) View more	Negative	09 Jul 2022
				ChAdOx1 nCoV-19	vtpavrhaqn(cfbinqzxzq) = rigyihyjbi kronnnolib (lrkbshejup ) View more
ISTH2022	Not Applicable	Purpura, Thrombocytopenic, Idiopathic anti-platelet factor 4 (PF4) antibody	96	ChAdOx1 nCov-19	augevervdo(ngornatcom) = oreddcctss lefuqkobes (xdntagsnfu ) View more	-	09 Jul 2022
ISTH2022	Not Applicable	Thrombocytopenia	-	2nd dose AZD1222	oldvjguecl(byonxnjqce) = Three catastrophic cases including 2 fatalities occurred. Concomitant factors were present in all and influenced outcome severity. lcomwrcwkx (dyavilqpby )	-	09 Jul 2022
ASCO2022	Not Applicable	Malignant Solid Neoplasm	399	ChAdOx1-nCoV-19 vaccine (Solid malignancy patients on active cancer treatment)	kitemadpyi(dqtkjnssbn) = uxxbbsfqzz qedlxvrfrk (pxmaulynlx ) View more	Positive	02 Jun 2022
				ChAdOx1-nCoV-19 vaccine (Healthy controls)	kitemadpyi(dqtkjnssbn) = oebonxsrvi qedlxvrfrk (pxmaulynlx ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis